ejpmr, 2024, 11(8), 670-680

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

COMPARATIVE ANALYSIS OF CHANDIPURA VIRUS AND NIPAH VIRUS

Princy R.*[1] and Nebin Sajeer[2]

[1]Pharm. D, The Dale View College of Pharmacy and Research Center, Trivandrum.
princyrajan826@gmail.com

[2]Pharm. D, The Dale View College of Pharmacy and Research Center, Trivandrum.
nebinsajeer@gmail.com

***Corresponding Author: Princy R.**

Pharm. D, The Dale View College of Pharmacy and Research Center, Trivandrum.

Email id: princyrajan826@gmail.com

Article Received on 27/06/2024 **Article Revised on 17/07/2024** **Article Accepted on 07/08/2024**

ABSTRACT

Viral illnesses represent substantial public health issues worldwide, with some pathogens having distinct regional effects. This review compares Chandipura virus (CHPV) with Nipah virus (NiV), examining their virology, epidemiology, clinical symptoms, pathogenesis, transmission dynamics, diagnosis, prevention, and control. CHPV, a member of the Rhabdoviridae family, mostly affects parts of India, causing acute encephalitis with significant fatality rates. NiV, a member of the Paramyxoviridae family, has a greater geographic distribution, including Southeast Asia, and is associated with severe respiratory and neurological symptoms. The review highlights variations and similarities in the viruses' illness mechanisms, transmission routes, and public health implications. It also outlines research gaps and avenues for further exploration, such as vaccine development and antiviral medicines. The potential for both viruses to generate endemic or pandemic outbreaks highlights the importance of global planning and response strategies. Understanding these viruses' properties and effects is critical for developing effective management and prevention methods.

KEYWORDS: Chandipura virus, Nipah virus, comparative analysis, virology, epidemiology, clinical manifestations, pathophysiology, transmission, diagnosis, prevention, global health preparedness.

INTRODUTION

Every year, viral illnesses claim millions of lives worldwide and pose a serious threat to public health. The diversity and spread of viral diseases continue to represent a challenge to global public health systems. Viruses, with their unique ability to change and adapt, cause a wide range of diseases, from minor infections to serious and life-threatening conditions. This review article is to provide a complete overview of viral infections worldwide, with a particular emphasis on their frequency and impact in India. It will also look at the most frequent viruses in India and how Chandipura and Nipah viruses stack up against them. Viral illnesses cause a significant morbidity and mortality burden around the world. Common viral diseases such the influenza virus, human immunodeficiency virus (HIV), hepatitis viruses, and coronaviruses have caused pandemics and epidemics, posing severe healthcare issues. For example, the influenza virus, with its seasonal outbreaks, causes millions of infections and many deaths each year. Despite breakthroughs in treatment, HIV continues to be a global pandemic, infecting millions of people. Hepatitis viruses, particularly Hepatitis B and C, are leading causes of chronic liver disease and malignancy. The recent COVID-19 pandemic, caused by the SARS-CoV-2 virus, demonstrated the deadly potential of viral illnesses, underlining the need for strong surveillance, prevention, and treatment measures.[1,2,3]

VIRAL DISEASES IN INDIA

India's enormous population and diverse topography present a unique set of challenges in treating viral infections. The tropical temperature, large population density, and diverse socioeconomic conditions all contribute to the spread and incidence of viral diseases. Dengue, chikungunya, hepatitis, and influenza are among the most frequent viral infections in India. Dengue and chikungunya, both spread by Aedes mosquitos, are common in urban and semi-urban regions, resulting in recurrent outbreaks and serious public health problems. Hepatitis B and C infections are common, causing chronic liver disorders and demanding comprehensive screening and vaccination programs.[4,5]

In addition to these common viral illnesses, India has had epidemics of rare but very virulent viruses such as the Chandipura and Nipah viruses. These viruses, while not as common as others, have caused major outbreaks with

high fatality rates, highlighting their potential harm to public health.

The Chandipura virus, while not as prevalent as the other viruses, is notable due to its high fatality rates during epidemics. It was first identified in Maharashtra in 1965 and causes acute encephalitis, particularly in children. Sandflies spread the virus, and outbreaks have occurred on a rare basis throughout India. Despite its low prevalence, the severity of illness and quick course of the disease make Chandipura virus a significant concern.

Nipah virus is another new pathogen that has produced significant outbreaks in India, most notably in West Bengal and Kerala. The virus, which was first detected in Malaysia in 1998 and then in India in 2001, is zoonotic, with fruit bats serving as the natural reservoir. Human-to-human transmission may occur, particularly in clinical settings. Despite its few outbreaks, Nipah virus remains a serious public health issue due to its high case fatality rate, potential for human-to-human transmission, and lack of particular therapies or vaccinations.

While Chandipura and Nipah viruses are less common than dengue, chikungunya, hepatitis, influenza, and HIV, they have a disproportionately severe impact. Both the Chandipura virus, which causes acute encephalitis mostly in children, and the Nipah virus, which has a high fatality rate and the potential for epidemics, are crucial to public health. Their occasional but fatal breakouts demand targeted surveillance, study, and rapid reaction procedures to prevent and control future occurrences.

In general, while familiar viral infections such as dengue, chikungunya, hepatitis, influenza, and HIV continue to dominate the Indian public health scene, new viruses such as Chandipura and Nipah pose substantial concerns due to their severity and outbreak potential. Understanding their epidemiology, transmission dynamics, and effects is critical for formulating and implementing effective public health interventions to reduce their threat.[6,7,8]

EPIDEMIOLOGY[9,10]

Epidemiology	Chandipura Virus	Nipah Virus
Global Prevalence	Rare, mostly confined to India	Endemic throughout South and Southeast Asia (e.g., Bangladesh, India, Malaysia)
Indian Prevalence	Reports are mostly from Maharashtra and Gujarat	Several outbreaks were reported in Kerala, West Bengal, and other areas
Global Incidence	Very low; localized cases reported mainly in India	Several outbreaks; hundreds of cases reported in various countries
Indian Incidence	Approximately 50 cases during significant outbreak in 2003	Over 300 cases reported in major outbreaks (2001, 2004, 2007, 2018)
Notable Outbreaks	2003 outbreak in India with a notable case count	Major outbreaks: Malaysia (1998), Bangladesh (2001, 2004), India (2007, 2018)

HISTORICAL BACKGROUND AND DISCOVERY[11,12]

History	Chandipura Virus	Nipah Virus
Historical Background	- **Region of Discovery**: India.	- **Region of Discovery**: Malaysia and Bangladesh.
	- **Initial Identification**: In 1965 by Dr. K. S. Prasad and colleagues.	- **Initial Identification**: In 1999 during an outbreak in Malaysia.
	- **Original Name**: Named after the Chandipura village in Maharashtra, India.	- **Original Name**: Named after the village of Nipah in Malaysia.
	- **Initial Cases**: Identified in Maharashtra and Andhra Pradesh, India.	- **Initial Cases**: Associated with an outbreak among pig farmers and later human cases.
	- **Epidemiological Pattern**: Regional, with outbreaks primarily in India.	- **Epidemiological Pattern**: Notable outbreaks in Malaysia, Bangladesh, and India.
Discovery Details	- **Discoverers**: Dr. K. S. Prasad and colleagues.	- **Discoverers**: Identified by a team led by Dr. S. S. Lam in Malaysia.
	- **Research Findings**: Linked to encephalitis cases; later studies confirmed its viral nature.	- **Research Findings**: Initially linked to a swine respiratory disease and later confirmed as a zoonotic virus causing encephalitis.
	- **Historical Impact**: Limited to specific regions with sporadic outbreaks; less globally recognized compared to Nipah.	- **Historical Impact**: Major global health concern due to high fatality rates and zoonotic potential.

	- **Public Health Response**: Focused on understanding the virus and managing outbreaks regionally.	- **Public Health Response**: International focus on control measures, research on transmission, and vaccine development.

STRUCTURE AND GENETICAL COMPOSITION[13,14,15]

Structure and genetic composition	Chandipura Virus	Nipah Virus
Virus Family	Rhabdoviridae	Paramyxoviridae
Virus Genus	Chandipura virus is classified under the genus Vesiculovirus	Nipah virus is classified under the genus Henipavirus
Virus Shape	Bullet-shaped	Spherical or pleomorphic
Envelope	Yes, the virus has an envelope derived from the host cell membrane	Yes, the virus has an envelope derived from the host cell membrane
Surface Proteins	Contains glycoproteins (G) that are crucial for attachment and entry	Contains surface glycoproteins (G) and fusion proteins (F) involved in attachment and fusion
Genomic Material	Single-stranded RNA (ssRNA)	Single-stranded RNA (ssRNA)
Genome Size	Approximately 11 kb (kilobases)	Approximately 15.2 kb (kilobases)
Genomic Structure	Linear RNA, coding for 5 main proteins (N, P, M, G, L)	Linear RNA, coding for 6 main proteins (N, P, M, F, G, L)
Nucleocapsid	Encapsulated with nucleoprotein (N), forming a helical symmetry	Encapsulated with nucleoprotein (N), forming a helical symmetry
Replication Site	Cytoplasm of the host cell	Cytoplasm of the host cell
Key Proteins	- Nucleoprotein (N): Encapsidates the RNA genome	- Nucleoprotein (N): Encapsidates the RNA genome
	- Phosphoprotein (P): Involved in viral transcription and replication	- Phosphoprotein (P): Involved in viral transcription and replication
	- Matrix protein (M): Assists in virus assembly	- Matrix protein (M): Assists in virus assembly
	- Glycoprotein (G): Facilitates attachment and entry into host cells	- Glycoprotein (G): Facilitates attachment and entry into host cells
	- Large polymerase protein (L): Responsible for RNA synthesis	- Fusion protein (F): Facilitates fusion of viral and host cell membranes
Pathogenesis	Causes encephalitis and febrile illness in humans	Causes severe respiratory illness and encephalitis in humans

MECHANISM OF ACTION[16,17,18]

Mechanism of Action	Chandipura Virus	Nipah Virus
Entry into Host Cells	**Attachment:** Glycoprotein (G) binds to cell surface receptors. **Entry:** Virus enters cells through endocytosis.	**Attachment:** Glycoprotein (G) binds to cell surface receptors. **Entry:** Virus enters cells via direct fusion with the cell membrane or endocytosis.
Cellular Target	Primarily infects neurons, leading to encephalitis.	Targets a range of cells including epithelial cells in the respiratory tract, endothelial cells, and neurons.
Viral Fusion	Glycoprotein (G) facilitates fusion of viral envelope with host cell membrane.	Fusion protein (F) mediates fusion of the viral envelope with the host cell membrane or through endosomes.
Replication Site	Replication occurs in the cytoplasm of infected cells.	Replication occurs in the cytoplasm of infected cells.
Genome Release	After entry, the viral nucleocapsid is released into the cytoplasm.	The viral nucleocapsid is released into the cytoplasm following fusion or endocytosis.
Transcription and Replication	Viral RNA serves as a template for transcription and replication by the viral polymerase (L).	Viral RNA serves as a template for transcription and replication by the viral polymerase (L).

Protein Synthesis	Viral proteins are synthesized in the cytoplasm, including structural proteins (N, P, M, G) and the polymerase (L).	Viral proteins are synthesized in the cytoplasm, including structural proteins (N, P, M, F, G) and the polymerase (L).
Assembly	Viral assembly occurs in the cytoplasm, where new viral particles are assembled and budded out of the cell membrane.	Viral assembly also occurs in the cytoplasm, with new virions being assembled and budding out from the cell membrane.
Release of New Virions	New virions are released from the host cell by budding through the cell membrane.	New virions are released by budding through the host cell membrane.
Pathogenic Mechanism	Causes neuronal damage leading to encephalitis and febrile illness.	Causes a range of symptoms including respiratory illness, encephalitis, and in severe cases, death.
Immune Evasion	Mechanisms of immune evasion not well-defined; primarily focuses on avoiding immune detection during the acute phase.	Utilizes various strategies to evade the host immune response, including modulation of cytokine responses and suppression of immune signaling.

SYMPTOMS[19,20,21]

Symptoms	**Chandipura Virus**	**Nipah Virus**
Incubation Period	2-4 days.	5-14 days.
Initial Symptoms	- **Fever**: Often high-grade.	- **Fever**: Typically high-grade, often sudden onset.
	- **Headache**: Common early symptom.	- **Headache**: Severe, often prominent in early stages.
	- **Malaise**: General feeling of illness or discomfort.	- **Malaise**: General weakness and fatigue.
Neurological Symptoms	- **Encephalitis**: Inflammation of the brain, leading to seizures and altered consciousness.	- **Encephalitis**: Severe inflammation of the brain with symptoms such as seizures, confusion, and altered mental status.
	- **Altered Mental Status**: Confusion, disorientation.	- **Confusion**: Severe disorientation and mental status changes.
	- **Seizures**: Can occur as a result of encephalitis.	- **Seizures**: Common in severe cases of encephalitis.
Respiratory Symptoms	- **Respiratory Symptoms**: Generally mild or absent.	- **Respiratory Symptoms**: May include cough, sore throat, and difficulty breathing.
Gastrointestinal Symptoms	- **Gastrointestinal Issues**: Not typically prominent.	- **Gastrointestinal Symptoms**: Nausea, vomiting, and abdominal pain can occur.
Hemorrhagic Symptoms	- **Hemorrhagic Manifestations**: Occasionally observed in severe cases.	- **Hemorrhagic Manifestations**: Can occur, particularly in severe cases, presenting as bleeding gums, hematemesis, and melena.
Duration of Illness	- **Duration**: Illness can be acute, with a rapid progression.	- **Duration**: Illness duration varies; can be acute or chronic depending on severity and complications.
Outcome	- **Outcome**: Can be fatal, especially without timely medical intervention.	- **Outcome**: High fatality rate; recovery possible with intensive care, but some patients may suffer from long-term neurological complications.

Long-Term Effects	- **Long-Term Effects**: Neurological sequelae in survivors, such as cognitive deficits.	- **Long-Term Effects**: Neurological sequelae in survivors, including persistent cognitive impairment and behavioral changes.

TRANSMISSION[22,23,24]

Transmission	Chandipura Virus	Nipah Virus
Modes of Transmission	- **Primary Mode**: Likely transmitted through mosquito bites.	- **Primary Mode**: Direct contact with infected animals (e.g., bats, pigs) or contaminated materials.
	- **Secondary Mode**: Possible transmission through other vectors, though not well-documented.	- **Secondary Mode**: Human-to-human transmission through respiratory droplets and close contact.
Vector and Host Dynamics	- **Primary Vector**: Mosquitoes, particularly Culex species.	- **Primary Host**: Fruit bats (natural reservoirs).
	- **Secondary Hosts**: Suspected other insects, though less well-characterized.	- **Secondary Hosts**: Pigs (amplifying hosts); humans are incidental hosts.
	- **Host Range**: Mainly humans.	- **Host Range**: Fruit bats, pigs, and humans.
	- **Transmission Cycle**: Likely involves mosquito vectors biting infected hosts and then transmitting the virus to humans.	- **Transmission Cycle**: Involves bats shedding the virus in saliva, urine, or feces; pigs may contract the virus from bats and then transmit to humans.
Environmental Factors	- **Climate**: Endemic in tropical and subtropical regions, particularly where mosquito vectors are prevalent.	- **Climate**: Outbreaks occur in tropical and subtropical regions; often linked to monsoon seasons and high humidity.
	- **Seasonality**: Higher incidence during the rainy season when mosquito populations are high.	- **Seasonality**: Outbreaks are often associated with the rainy season, which increases the likelihood of human-animal interactions.
	- **Geographic Factors**: Concentrated in specific regions of India with suitable environmental conditions for mosquito breeding.	- **Geographic Factors**: Outbreaks often occur in rural areas with close proximity between animals and humans.
Sanitation and Hygiene	- **Sanitation**: Poor sanitation can contribute to higher mosquito breeding sites and increased transmission risk.	- **Sanitation**: Poor hygiene and handling of infected animals can facilitate transmission. Proper sanitation reduces the risk of infection.
	- **Preventive Measures**: Vector control through mosquito nets and insect repellents.	- **Preventive Measures**: Avoiding contact with sick animals, improving sanitation, and using protective measures.

DIAGNOSIS[25,26,27]

Diagnosis	Chandipura Virus	Nipah Virus
Clinical Diagnosis	- **Clinical Features**: Diagnosis based on symptoms such as fever, headache, and encephalitis.	- **Clinical Features**: Diagnosis based on symptoms such as high fever, encephalitis, and respiratory issues.
Laboratory Diagnostic Methods	- **RT-PCR**: Used to detect viral RNA in patient samples, such as blood or cerebrospinal fluid.	- **RT-PCR**: Essential for detecting viral RNA in blood, cerebrospinal fluid, or other bodily fluids.
	- **ELISA**: Enzyme-linked immunosorbent assay to detect antibodies against Chandipura virus.	- **ELISA**: Used for detecting antibodies against Nipah virus.
	- **Virus Isolation**: Culturing the virus from patient samples in cell cultures.	- **Virus Isolation**: Culturing the virus from patient samples in cell cultures, though this is less commonly used.

Serological Tests	- **Serology**: Detects antibodies produced in response to infection.	- **Serology**: Detects antibodies specific to Nipah virus, typically using ELISA.
Immunohistochemistry	- **IHC**: Used to detect viral antigens in tissue samples.	- **IHC**: Detects viral antigens in tissue samples from affected patients.
Molecular Techniques	- **Sequencing**: Genome sequencing for research and epidemiological studies.	- **Sequencing**: Genome sequencing to understand genetic variations and outbreaks.
Rapid Diagnostic Tests	- **RDTs**: Limited availability; primarily used in research settings.	- **RDTs**: Limited; focus on more sensitive and specific methods like PCR and serology.
Histopathology	- **Histopathology**: Examining tissue samples for characteristic changes caused by infection.	- **Histopathology**: Identifies tissue changes associated with Nipah virus infection.

TREATMENT[28,29,30]

Treatment	Chandipura Virus	Nipah Virus
Current Treatment Options	- **Supportive Care**: Main treatment involves supportive care to manage symptoms, such as fever, seizures, and encephalitis.	- **Supportive Care**: Essential for managing symptoms like fever, encephalitis, and respiratory issues.
	- **Antiviral Drugs**: No specific antiviral drugs approved for Chandipura Virus; research ongoing.	- **Antiviral Drugs**: No specific antiviral drugs approved; experimental treatments include ribavirin and favipiravir.
	- **Steroids**: Sometimes used to reduce inflammation in severe cases, but effectiveness is not well-established.	- **Steroids**: May be used to manage severe inflammation and swelling in cases of encephalitis.
Experimental Treatments	- **Research**: Ongoing research to identify potential antiviral therapies and vaccines.	- **Experimental Treatments**: Studies have investigated drugs like ribavirin and favipiravir; no FDA-approved treatment.
Vaccines	- **Vaccine Status**: No licensed vaccine available.	- **Vaccine Status**: No licensed vaccine available; research is ongoing.
Management of Complications	- **Seizure Management**: Anti-seizure medications may be prescribed.	- **Seizure Management**: Anti-seizure medications used as needed.
	- **Neurological Support**: Rehabilitation for neurological sequelae in survivors.	- **Neurological Support**: Rehabilitation for long-term neurological effects and cognitive impairments.
Preventive Measures	- **Vector Control**: Measures to control mosquito populations, such as insect repellents and mosquito nets.	- **Preventive Measures**: Avoiding contact with infected animals, improving sanitation, and using protective measures.
Public Health Interventions	- **Surveillance**: Monitoring for outbreaks and reporting cases to public health authorities.	- **Public Health Interventions**: Contact tracing, quarantine of exposed individuals, and public health advisories.

PREVENTIVE MEASURES[31,32,33]

Preventive Measures	Chandipura Virus	Nipah Virus
General Preventive Measures	- **Vector Control**: Reducing mosquito populations through environmental management (e.g., eliminating standing water) and personal protection (e.g., insect repellents, mosquito nets).	- **Avoiding Contact with Animals**: Preventing contact with bats and pigs, especially in outbreak areas.
	- **Public Awareness**: Educating communities about mosquito-borne	- **Public Awareness**: Educating communities about avoiding contact

	diseases and how to prevent mosquito bites.	with infected animals and recognizing symptoms of Nipah virus infection.
Personal Protection	- **Use of Insect Repellents**: Applying repellents containing DEET or other effective ingredients.	- **Protective Clothing**: Wearing protective clothing when in areas with a high risk of exposure to infected animals.
	- **Mosquito Nets**: Using bed nets, particularly in areas with high mosquito populations.	- **Hand Hygiene**: Regular hand washing, especially after handling animals or contaminated materials.
Animal Control	- **Animal Surveillance**: Monitoring and controlling animal populations in areas where outbreaks are known to occur.	- **Animal Surveillance**: Monitoring and culling infected animals (e.g., pigs) during outbreaks to prevent further spread.
	- **Vaccination of Animals**: No specific vaccines for Chandipura Virus in animals; focus on mosquito control instead.	- **Vaccination of Animals**: No specific vaccines for Nipah Virus in animals; surveillance and control measures are key.
Public Health Interventions	- **Outbreak Response**: Coordinated response to manage and contain outbreaks, including vector control and public health advisories.	- **Outbreak Response**: Rapid response to contain outbreaks, including contact tracing, quarantine, and infection control measures.
Travel and Trade Precautions	- **Travel Advisories**: Issued in case of outbreaks to inform travelers about risks and preventive measures.	- **Travel Advisories**: Issued to limit movement from outbreak areas and prevent the spread of infection.
Research and Development	- **Ongoing Research**: Investigating potential vaccines and antiviral treatments.	- **Ongoing Research**: Developing vaccines, treatments, and improved diagnostic tools.

FUTURE DIRECTIONS

Future research priorities for Chandipura and Nipah viruses include gaining a full understanding of their pathogenesis, transmission dynamics, and ecological reservoirs. There are still research gaps in understanding the specific molecular mechanisms by which these viruses penetrate and reproduce within host cells. Furthermore, the involvement of wildlife and environmental elements in viral transmission is poorly understood. Understanding the entire range of disease presentation and long-term consequences in human situations is equally critical. To detect and contain outbreaks as quickly as possible, surveillance systems must be expanded and diagnostic instruments improved. More research is needed to determine the genetic variants of these viruses and their effects on virulence and transmission. Collaborative efforts across disciplines, such as virology, epidemiology, and ecology, are required to close knowledge gaps and increase preparedness for future outbreaks.[34,35]

POTENTIAL FOR VACCINE DEVELOPMENT

Chandipura Virus

Developing a vaccine for Chandipura virus is an important yet difficult task. The virus, a member of the Rhabdoviridae family, has not made significant progress in vaccine research. However, the core technique entails identifying viral antigens that may trigger a protective immune response. Potential vaccination techniques may include:

1. **Inactivated or Killed Vaccines:** These vaccinations use inactivated viral particles to boost immunity without producing illness. This technique has worked for other viruses, but it requires extensive validation for the Chandipura virus.
2. **Recombinant Protein Vaccines:** Using recombinant DNA technology, these vaccines create specific viral proteins to induce immunity. This technique provides the advantage of focusing on certain viral components.
3. **Viral Vector-Based Vaccines:** Using a harmless virus to convey Chandipura virus antigens may boost immune responses. This method is being tested for different viral infections and shows promise.[36,37]

Nipah Virus

The Nipah virus vaccine is further along in development than the Chandipura virus. Several vaccine candidates are in different phases of research and development:

1. **Subunit Vaccines:** These vaccines use isolated proteins from the Nipah virus to boost the immune system. They are now undergoing preclinical and early clinical testing.
2. **Viral Vector Vaccines:** These vaccines utilize a modified virus to deliver Nipah virus antigens. Some candidates have showed promise in preclinical investigations, indicating the possibility for robust and long-lasting immunity.
3. **mRNA Vaccines:** Nipah virus vaccines are being developed using the same approach as COVID-19 vaccines. They provide the advantages of quick development and flexibility in antigen design.

4. **DNA Vaccines:** Researchers are exploring DNA-based vaccinations that encode Nipah virus proteins. These vaccines have demonstrated potential in animal models.[38,39]

ADVANCES IN ANTIVIRAL THERAPIES

Chandipura Virus

There are currently no licensed antiviral medicines for the Chandipura virus. Infections are mostly managed as supportive care, with an emphasis on symptomatic alleviation and neurological symptoms.

1. **Antiviral Drug Development:** Research on medications that target viral replication or prevent virus entry may be advantageous. This could include testing existing antiviral medicines for efficacy against the Chandipura virus or designing novel molecules that precisely target the virus.
2. **Monoclonal Antibodies:** Creating monoclonal antibodies to neutralize the Chandipura virus could provide a tailored treatment approach. This necessitates substantial study to identify and create potent antibodies.

Nipah Virus

Currently, no particular antiviral medications have been authorized for Nipah virus infections. Management is providing supportive care, such as keeping hydrated and dealing with difficulties.

Advances in Antiviral Therapies

1. **Monoclonal Antibodies:** Research on monoclonal antibodies targeting Nipah virus shows promise. Monoclonal antibodies, such as m102.4, have shown efficacy in preclinical tests and are being investigated for clinical usage.
2. **Antiviral Drugs:** Research is underway to develop medications that prevent Nipah virus multiplication. Drugs like favipiravir and ribavirin, for example, have been evaluated for efficacy against the Nipah virus in vitro and on animals.
3. **Host-Targeted Therapies:** Understanding Nipah virus host-cell interactions could lead to medicines that improve viral clearance by modulating the host immune response.
4. **Combination Therapies:** Combining antiviral medications with supportive and immunomodulatory therapies may improve outcomes. Research on synergistic effects and appropriate treatment regimes is still ongoing.

Although vaccine development for the Chandipura virus is still in its early phases, vaccine development for the Nipah virus is moving forward, with numerous options being investigated. Advances in antiviral medicines for both viruses are focusing on tailored treatments and supportive care. Continued research and investment are critical in creating viable vaccines and medicines to tackle these new viral threats.[40,41]

THE NEED FOR GLOBAL PREPAREDNESS AND RESPONSE APPROACHES

The advent and re-emergence of viral illnesses like Chandipura and Nipah emphasize the crucial importance of strong global preparedness and response programs. Given the unexpected nature of viral outbreaks and their potential to cause major health crises, countries must be ready with comprehensive preparedness plans that include surveillance, fast reaction, and mitigation measures.

1. **Surveillance and Early Detection:** Effective surveillance systems are essential for early detection of viral outbreaks. This entails tracking both human and animal health data, as well as environmental indications that may indicate the presence of new viruses. Early detection enables timely intervention, potentially limiting outbreaks before they spread.
2. **Rapid Response Mechanisms:** One aspect of global readiness is the development and maintenance of quick reaction capabilities, such as medical supply, vaccine, and antiviral medicine stocks. Countries must develop standards for the rapid deployment of resources and coordination among public health organizations, healthcare professionals, and emergency personnel.
3. **Public Health Infrastructure:** Investing in healthcare infrastructure and capacity building is critical to effectively managing epidemics. This includes improving diagnostic laboratories, increasing healthcare facilities, and educating healthcare personnel on outbreak management and infection control.
4. **Communication and Information Sharing:** Clear communication techniques and information sharing between countries and international organizations are essential. This guarantees that correct information on outbreaks, preventative strategies, and treatment alternatives is distributed swiftly and efficiently, reducing misunderstanding and panic.
5. **Research and Development:** Continued research is required to provide novel vaccines, antiviral medicines, and diagnostic tools. Funding for research and engagement with academic institutions and industry partners can speed up the creation of these vital resources.[42,43,44]

THE SIGNIFICANCE OF GLOBAL COLLABORATION ALONG WITH HOLISTIC HEALTH APPROACHES

1. **International Cooperation:** The worldwide character of viral epidemics needs international cooperation in disease management and control. Collaboration between countries, international organizations (such as the World Health Organization), and non-governmental organizations is critical for exchanging data, resources, and expertise. Joint efforts can improve the ability to identify and respond to epidemics that span national borders, as well as coordinate vaccination programs and treatment plans.

2. **Integrated One Health Approaches:** The One Health concept acknowledges the link between human, animal, and environmental health. This integrated approach is critical for treating zoonotic illnesses such as Nipah virus, which start in animal populations and can spread to people. One Health initiatives address the underlying causes of illness onset and transmission by integrating veterinarian health, wildlife monitoring, and environmental surveillance into public health strategies.
3. **Ecological and Environmental Monitoring:** Understanding and monitoring biological and environmental factors, such as habitat changes and climate variability, can aid in the prediction and prevention of epidemics. Changes in bat populations or agricultural practices, for example, can have an impact on how zoonotic viruses spread.
4. **Collaborative Research and Data Sharing:** Sharing research findings and epidemiology data across borders improves understanding of viral behavior and allows for the creation of effective control methods. Collaborative research can also lead to the identification of new treatment targets and the development of novel epidemic management strategies.
5. **Capacity Building and Training:** International cooperation can help healthcare professionals, veterinarians, and environmental scientists develop their skills and knowledge. This ensures that staff have the skills and information required to detect, prevent, and respond to viral threats efficiently.

Global preparedness and response plans, backed by international cooperation and integrated One Health methods, are critical for managing and minimizing the effect of viral infections. The global community may improve its ability to deal with existing and future viral risks by encouraging collaboration, investing in research and infrastructure, and taking a holistic approach to health.[45,46,47]

CONCLUSION

This review emphasizes the different and overlapping characteristics of the Chandipura and Nipah viruses, as well as their important public health implications. Chandipura virus, which mostly affects regions in India, poses a significant challenge due to its high fatality rate and quick progression to severe encephalitis. Nipah virus, which has a greater geographical reach, offers a significant hazard because to its potential for severe respiratory and neurological consequences, as well as its ability to generate epidemics in a variety of contexts.

The comparative analysis sheds light on the virology, epidemiology, clinical presentations, and pathophysiological mechanisms of these viruses. While CHPV and NiV have comparable RNA genomes and are negative-sense, their transmission patterns and clinical consequences differ significantly. This distinction is critical to customizing public health policies and interventions.

The analysis also identifies major research gaps and opportunities for further study, such as the development of effective vaccinations and antiviral therapies. Both viruses have the potential to create endemic or pandemic epidemics, thus global preparedness and response plans are critical. Strengthening surveillance systems, improving diagnostic skills, and implementing strong prevention efforts are all critical steps toward reducing the effect of these infections.

Finally, recognizing the similarities and differences between the Chandipura and Nipah viruses is critical for strengthening public health response and preparedness. Continued research and international collaboration will be critical in tackling the problems posed by these viruses, as well as creating prevention and control techniques for future outbreaks.

REFERENCES

1. Devaux CA. Emerging and re-emerging viruses: A global challenge illustrated by Chikungunya virus outbreaks. World J Virol, Feb. 12, 2012; 1(1): 11-22.
2. Mourya DT, Yadav PD, Ullas PT, Bhardwaj SD, Sahay RR, Chadha MS, Shete AM, Jadhav S, Gupta N, Gangakhedkar RR, Khasnobis P, Singh SK. Emerging/re-emerging viral diseases & new viruses on the Indian horizon. Indian J Med Res., Apr. 2019; 149(4): 447-467.
3. Mani RS, Ravi V, Desai A, Madhusudana SN. Emerging Viral Infections in India. Proc Natl Acad Sci India Sect B Biol Sci., 2012; 82(1): 5-21.
4. Bankar NJ, Tidake AA, Bandre GR, Ambad R, Makade JG, Hawale DV. Emerging and Re-Emerging Viral Infections: An Indian Perspective. Cureus, Oct. 8, 2022; 14(10): e30062.
5. Mohammad K. Parvez, Shama Parveen; Evolution and Emergence of Pathogenic Viruses: Past, Present, and Future. *Intervirology,* 5 October, 2017; 60(1-2): 1–7.
6. Sudeep AB, Gurav YK, Bondre VP. Changing clinical scenario in Chandipura virus infection. Indian J Med Res., Jun. 2016; 143(6): 712-721.
7. Gurav, Yogesh & Tandale, Babasaheb & Jadi, Ramesh & Gunjikar, Rashmi & Tikute, Sanjaykumar & Jamgaonkar, Aniruddha & Khadse, Ravindra & Jalgaonkar, Suresh & Arankalle, Vidya & Mishra, Akhilesh. (2010). Chandipura virus encephalitis outbreak among children in Nagpur division, Maharashtra, The Indian journal of medical research, 2007; 132: 395-9.
8. Sapkal GN, Sawant PM, Mourya DT. Chandipura Viral Encephalitis: A Brief Review. Open Virol J., Aug. 31, 2018; 12: 44-51.
9. Singh RK, Dhama K, Chakraborty S, Tiwari R, Natesan S, Khandia R, Munjal A, Vora KS, Latheef SK, Karthik K, Singh Malik Y, Singh R, Chaicumpa

W, Mourya DT. Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review. Vet Q., Dec. 2019; 39(1): 26-55.
10. Menghani S, Chikhale R, Raval A, Wadibhasme P, Khedekar P. Chandipura Virus: an emerging tropical pathogen. Acta Trop., Oct. 2012; 124(1): 1-14.
11. Bruno L, Nappo MA, Ferrari L, Di Lecce R, Guarnieri C, Cantoni AM, Corradi A. Nipah Virus Disease: Epidemiological, Clinical, Diagnostic and Legislative Aspects of This Unpredictable Emerging Zoonosis. *Animals*, 2023; 13(1): 159.
12. Epstein JH, Field HE, Luby S, Pulliam JR, Daszak P. Nipah virus: impact, origins, and causes of emergence. Curr Infect Dis Rep., Jan. 2006; 8(1): 59-65.
13. Basak S, Mondal A, Polley S, Mukhopadhyay S, Chattopadhyay D. Reviewing Chandipura: a vesiculovirus in human epidemics. Biosci Rep., Oct. 2007; 27(4-5): 275-98.
14. Sun B, Jia L, Liang B, Chen Q, Liu D. Phylogeography, Transmission, and Viral Proteins of Nipah Virus. Virol Sin., Oct. 2018; 33(5): 385-393.
15. Avinash AV, Prabhakar SS, Madhukar WA; Hanumaih,*; Pawar SD, Chandra MA. G, N, and P gene-based analysis of Chandipura viruses, India. Emerg Infect Dis., Jan. 2005; 11(1): 123-126.
16. Talukdar P, Dutta D, Ghosh E, Bose I, Bhattacharjee S. Molecular Pathogenesis of Nipah Virus. Appl Biochem Biotechnol, Apr. 2023; 195(4): 2451-2462.
17. Tandale, Babasaheb & Tikute, Sanjaykumar & Arankalle, Vidya & Sathe, Padmakar & Joshi, Manohar & Ranadive, Satish & Kanojia, Phoolchand & Eshwarachary, D & Kumarswamy, M & Mishra, Akhilesh. Chandipura virus: A major cause of acute encephalitis in children in North Telangana, Andhra Pradesh, India. Journal of medical virology, 2008; 80: 118-24.
18. Kavathekar VK, Dhanavade MJ, Sonawane KD, Balakrishnan A. Role of cell surface vimentin in Chandipura virus replication in Neuro-2a cells. Virus Res., Aug. 2020; 285: 198014.
19. Banerjee S, Gupta N, Kodan P, Mittal A, Ray Y, Nischal N, Soneja M, Biswas A, Wig N. Nipah virus disease: A rare and intractable disease. Intractable Rare Dis Res., Feb. 2019; 8(1): 1-8.
20. Garbuglia AR, Lapa D, Pauciullo S, Raoul H, Pannetier D. Nipah Virus: An Overview of the Current Status of Diagnostics and Their Role in Preparedness in Endemic Countries. *Viruses*, 2023; 15(10): 2062.
21. Islam MR, Dhar PS, Rahman MM. Newly outbreak of Nipah virus: epidemiology, symptoms, transmission, diagnostic testing, treatment, and global health concern. Int J Surg, Mar. 1, 2023; 109(3): 507-508.
22. Rao BL, Basu A, Wairagkar NS, Gore MM, Arankalle VA, Thakare JP, Jadi RS, Rao KA, Mishra AC. A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus. Lancet, Sep. 4-10, 2004; 364(9437): 869-74.
23. Basak S, Mondal A, Polley S, Mukhopadhyay S, Chattopadhyay D. Reviewing Chandipura: a vesiculovirus in human epidemics. Biosci Rep., Oct. 2007; 27(4-5): 275-98.
24. Faus-Cotino J, Reina G, Pueyo J. Nipah Virus: A Multidimensional Update. *Viruses*, 2024; 16(2): 179.
25. Garbuglia AR, Lapa D, Pauciullo S, Raoul H, Pannetier D. Nipah Virus: An Overview of the Current Status of Diagnostics and Their Role in Preparedness in Endemic Countries. Viruses, Oct. 7, 2023; 15(10): 2062.
26. Bruno L, Nappo MA, Ferrari L, Di Lecce R, Guarnieri C, Cantoni AM, Corradi A. Nipah Virus Disease: Epidemiological, Clinical, Diagnostic and Legislative Aspects of This Unpredictable Emerging Zoonosis. *Animals*, 2023; 13(1): 159.
27. Qin D. Next-generation sequencing and its clinical application. Cancer Biol Med., Feb. 2019; 16(1): 4-10.
28. Johnson K, Vu M, Freiberg AN. Recent advances in combating Nipah virus. Fac Rev., Sep. 29, 2021; 10: 74.
29. Banerjee S, Gupta N, Kodan P, Mittal A, Ray Y, Nischal N, Soneja M, Biswas A, Wig N. Nipah virus disease: A rare and intractable disease. Intractable Rare Dis Res., Feb. 2019; 8(1): 1-8.
30. Sapkal GN, Sawant PM, Mourya DT. Chandipura Viral Encephalitis: A Brief Review. Open Virol J., Aug. 31, 2018; 12: 44-51.
31. Sudeep AB, Gurav YK, Bondre VP. Changing clinical scenario in Chandipura virus infection. Indian J Med Res., Jun. 2016; 143(6): 712-721.
32. Urmi TJ, Dewan SMR, Rahman JM, Sharmin SN, Hassan MM. Development of Preventive Measures and Treatment Strategies Against Nipah Virus is a Timely Need: Bangladeshi Perspective. Clin Pathol, Jun. 20, 2023; 16: 2632010X231183314.
33. Ellwanger JH, Veiga ABG, Kaminski VL, Valverde-Villegas JM, Freitas AWQ, Chies JAB. Control and prevention of infectious diseases from a One Health perspective. Genet Mol Biol., Jan. 29, 2021; 44(1,1): e20200256.
34. Soman Pillai V, Krishna G, Valiya Veettil M. Nipah Virus: Past Outbreaks and Future Containment. *Viruses*, 2020; 12(4): 465.
35. Gardy JL, Loman NJ. Towards a genomics-informed, real-time, global pathogen surveillance system. Nat Rev Genet, Jan. 2018; 19(1): 9-20.
36. Jadi RS, Sudeep AB, Barde PV, Arankalle VA, Mishra AC. Development of an inactivated candidate vaccine against Chandipura virus (Rhabdoviridae: Vesiculovirus). Vaccine, Jun. 20, 2011; 29(28): 4613-7.
37. Venkateswarlu CH, Arankalle VA. Recombinant glycoprotein based vaccine for Chandipura virus infection. Vaccine, May 11, 2009; 27(21): 2845-50.

38. Amaya M, Broder CC. Vaccines to Emerging Viruses: Nipah and Hendra. Annu Rev Virol, Sep 29, 2020; 7(1): 447-473.
39. Majee, Prativa & Jain, Neha & Kumar, Amit. Designing of a multi-epitope vaccine candidate against Nipah virus by in silico approach: A putative prophylactic solution for the deadly virus. Journal of Biomolecular Structure and Dynamics, 2020; 39: 1-39.
40. Pavitrakar, Daya & Bondre, Vijay. Antiviral effect of Favipiravir against Chandipura virus in vitro and in vivo. Journal of Medical Virology, 2023; 95.
41. Faus-Cotino J, Reina G, Pueyo J. Nipah Virus: A Multidimensional Update. *Viruses*, 2024; 16(2): 179.
42. Okesanya OJ, Agbo KC, Jamil S, Lucero-Prisno Iii DE. Emerging threat: Nipah virus - A call for global preparedness and vigilance. New Microbes New Infect., Mar. 11, 2024; 58: 101237.
43. Koopmans M. Surveillance strategy for early detection of unusual infectious disease events. Curr Opin Virol, Apr. 2013; 3(2): 185-91.
44. Albright K, Navarro EI, Jarad I, Boyd MR, Powell BJ, Lewis CC. Communication strategies to facilitate the implementation of new clinical practices: a qualitative study of community mental health therapists. Transl Behav Med., Feb. 16, 2022; 12(2): 324-334.
45. Fanning JP, Murthy S, Obonyo NG, Baillie JK, Webb S, Dalton HJ, Fraser JF. Global infectious disease research collaborations in crises: building capacity and inclusivity through cooperation. Global Health, Jul. 26, 2021; 17(1): 84.
46. Hayman DT, Bowen RA, Cryan PM, McCracken GF, O'Shea TJ, Peel AJ, Gilbert A, Webb CT, Wood JL. Ecology of zoonotic infectious diseases in bats: current knowledge and future directions. Zoonoses Public Health, Feb. 2013; 60(1): 2-21.
47. Doble A, Sheridan Z, Razavi A, Wilson A, Okereke E. The role of international support programmes in global health security capacity building: A scoping review. PLOS Glob Public Health, Apr. 5, 2023; 3(4): e0001763.